Working… Menu

A Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00333476
Recruitment Status : Terminated
First Posted : June 5, 2006
Last Update Posted : November 28, 2007
Information provided by:
Genaera Corporation

Brief Summary:
Age-Related Macular Degeneration (AMD) is a degenerative eye disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of legal blindness among adults age 50 or older in the Western world. AMD presents in two different types - "dry" and the more severe "wet" form. Wet AMD is caused by the growth of abnormal blood vessels in the macula. Squalamine lactate is an investigational drug that may prevent the growth of these abnormal blood vessels. This study will test the safety and efficacy of Squalamine in the treatment of AMD.

Condition or disease Intervention/treatment Phase
Macular Degeneration Drug: MSI-1256F (Squalamine Lactate) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 140 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: A Phase 2, Randomized, Open Label, Safety, and Pharmacodynamic Study of Squalamine Lactate for Injection for the Treatment of Minimally Classic or Active Occult Choroidal Neovascularization Associated With Age-Related Macular Degeneration
Study Start Date : May 2006

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. To evaluate the safety profile of squalamine lactate at doses ranging from 40 mg to 160 mg of squalamine lactate

Secondary Outcome Measures :
  1. To evaluate short-term effects on best corrected visual acuity and changes in subretinal CNV as measured by optical coherence tomography
  2. To evaluate short-term effects on best corrected visual acuity and changes in subretinal CNV as measured by fluorescein angiography

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult subjects ≥ 50 years of age.
  • minimally classic or active occult choroidal neovascularization associated with age-related macular degeneration in one or both eyes.
  • baseline best corrected visual acuity score between 35 to 65 letters according to the Early Treatment of Diabetic Retinopathy Study protocol.
  • central retinal thickness by optical coherence tomography of > 250 microns.
  • lesions > 9 disc areas.
  • > 25% fibrosis in the lesion.

Exclusion Criteria:

  • Previous history of triamcinolone, bevacizumab, ranibizumab, or pegaptanib sodium injection therapy in the study eye.
  • retinal or optic nerve disease.
  • uncontrolled diabetes.
  • ongoing malignancy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00333476

Layout table for location information
United States, Florida
Florida Eye Microsurgical Institute
Boynton Beach, Florida, United States, 33426
Retina Health Center
Fort Meyers, Florida, United States, 33907
Bascom Palmer Eye Institute
Miami, Florida, United States, 33136
United States, Indiana
Midwest Eye Institute
Indianapolis, Indiana, United States, 46280
United States, Maryland
Retina Specialists
Towson, Maryland, United States, 21204
United States, Missouri
Eye Foundation of Kansas City
Kansas City, Missouri, United States, 64108
United States, New York
Ophthalmic Consultants of Long Island
Long Island, New York, United States, 11563
Retina Associates of Western New York
Rochester, New York, United States, 14618
United States, Texas
Charles Garcia, MD, P.A.
Houston, Texas, United States, 77002
Sponsors and Collaborators
Genaera Corporation
Layout table for investigator information
Principal Investigator: Randy Katz, MD Florida Eye Microsurgical Institute, Inc.
Principal Investigator: Alexander Eaton, MD Retina Health Center
Principal Investigator: Thomas Ciulla, MD Midwest Eye Institute
Principal Investigator: Raymond Sjaarda, MD Retina Specialists
Principal Investigator: Nelson Sabates, MD Eye Foundation of Kansas City
Principal Investigator: Charles Garcia, MD Charles Garcia, MD, P.A.
Principal Investigator: Glenn Stoller, MD Ophthalmic Consultants of Long Island
Principal Investigator: Phillip Rosenfeld, MD Bascom Palmer Eye Institute
Principal Investigator: Steven Rose, MD Retina Associates of Western New York
Layout table for additonal information Identifier: NCT00333476    
Other Study ID Numbers: MSI-1256F-212
First Posted: June 5, 2006    Key Record Dates
Last Update Posted: November 28, 2007
Last Verified: November 2007
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Anticarcinogenic Agents
Protective Agents
Physiological Effects of Drugs
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors